Abogen Announces Licensing and Option Agreement with Novartis to Advance mRNA-Encoded T-Cell Engager and other potential RNA programs

Summary

Abogen announced a licensing and option agreement with Novartis to advance an mRNA-encoded T-cell engager and other potential RNA programs. The partnership grants Novartis rights to develop and commercialize Abogen's RNA-based therapeutic candidates.